person
as of 2026-07-01Mathias Zink, MD
at a glance
Roles: Principal Investigator, Author
KOL signal score 6
2 publications · 1 high-value
Cross-drug reach: 2 competitor drugs
Synthesized from structured facts only — each point cited above.
Profile
Affiliation
Central Institute of Mental Health, Department of Psychiatry, Mannheim, Germany
Roles
Principal Investigator, Author
KOL signal
6
Publications
2 (1 high-value)
Trial investigator
no
Publishes on
2 drugs
Trials led
3
Treatment of MDEs During the Course of Psychotic Disorders With Duloxetine
NCT00224302Phase 4Completed
Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective Trial
NCT00224315Phase 4Completed
Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH)
NCT01822418Phase 4Completed
Publications & congress
2
Identifying differential predictors for treatment response to amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia: Results of the COMBINE-study.
Schizophrenia research · 2024 · high-value
New Pharmacological Treatment Approaches for Schizophrenia: Navigating the Post-iclepertin Landscape.
CNS drugs · 2026
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
publishes on